Correlation of the levels of angiotensin Ⅱ and angiotensin (1-7) with the degree of chronic hepatitis B liver fibrosis

Yu Chong; Gu YuLing; Li Min; Gu ErLi

doi:10.3969/j.issn.1001-5256.2019.11.015

Volume 35 Issue 11

Nov. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(11): 2461-2465

PDF( 1996 KB)

Correlation of the levels of angiotensin Ⅱ and angiotensin (1-7) with the degree of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.11.015

Department of Hepatology,Nantong Third Hospital Affiliated to Nantong University

Research funding:

Received Date: 2019-06-26
Published Date: 2019-11-20

Abstract

Abstract

Objective To investigate the differences in the plasma levels of angiotensin Ⅱ( Ang Ⅱ) and angiotensin( 1-7) [Ang( 1-7) ]in different stages among patients with chronic hepatitis B( CHB) liver fibrosis and their significance in the pathogenesis of liver fibrosis.Methods A prospective study was performed. A total of 86 patients with hepatitis B virus( HBV) infection who attended our hospital from March 2017 to March 2019 were enrolled and divided into CHB group( group A) with 25 patients,compensated hepatitis B cirrhosis group( group B) with 31 patients,and decompensated hepatitis B cirrhosis group( group C) with 30 patients. The double-antibody sandwich method was used to measure the plasma levels of Ang Ⅱ and Ang( 1-7),and FibroTouch scan was used for liver stiffness measurement( LSM). A one-way analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A binary linear correlation analysis was used to investigate the correlation of the plasma levels of Ang Ⅱ and Ang( 1-7) with LSM; a Spearman rank correlation analysis was used to investigate the correlation of the plasma levels of Ang Ⅱ and Ang( 1-7) with the progression of CHB liver fibrosis; a logistic regression analysis was used to evaluate the value of Ang Ⅱ,Ang( 1-7),and LSM in predicting hepatitis B cirrhosis. Results With the progression of liver fibrosis from group A to group C,there was a significant increase in course of disease( 5. 2 ± 1. 3 years vs 7. 8 ± 1. 6 years vs 10. 1 ± 1. 5 years,F = 4. 266,P = 0. 002),a significant reduction in the proportion of patients receiving antiviral therapy( 76. 00% vs 64. 52% vs 53. 33%,χ2= 5. 544,P < 0. 001),significant increases in Ang II( 51. 01 ±8. 68 pg/ml vs 74. 38 ± 10. 05 pg/ml vs 102. 78 ± 13. 22 pg/ml,F = 520. 260,P < 0. 001),Ang II/Ang( 1-7) ratio( 1. 06 ± 0. 41 vs2. 32 ± 0. 23 vs 5. 82 ± 1. 24,F = 18. 860,P < 0. 001),and LSM( 6. 85 ± 1. 26 kP a vs 18. 25 ± 3. 22 kP a vs 26. 84 ± 7. 57 kP a,F = 93. 260,P <0. 001),and a significant reduction in Ang( 1-7)( 45. 93 ± 10. 24 pg/ml vs 31. 52 ± 9. 62 pg/ml vs 16. 55 ± 9. 48 pg/ml,F = 209. 860,P <0. 001). Ang II and Ang II/Ang( 1-7) ratio were positively correlated with LSM( r = 0. 623 and 0. 813,both P < 0. 01),while Ang( 1-7) was negatively correlated with LSM( r =-0. 677,P < 0. 01). Ang II,Ang II/Ang( 1-7) ratio,and LSM gradually increased with the progression of liver fibrosis( r = 0. 639,0. 886,and 0. 712,all P < 0. 01),while Ang( 1-7) was negatively correlated with the progression of liver fibrosis( r =-0. 653,P < 0. 01). Ang II/Ang( 1-7) ratio and LSM had an early warning effect for liver cirrhosis in patients with HBV infection( odds ratio = 1. 884 and 2. 015,both P < 0. 01). Conclusion In patients with HBV infection,there are gradual increases in Ang II and Ang II/Ang( 1-7) ratio and a gradual reduction in Ang( 1-7) with the aggravation of liver fibrosis. Dynamic monitoring of the plasma levels of Ang II and Ang( 1-7) can provide a reference for real-time assessment of liver fibrosis and decision-making in clinical diagnosis and treatment.
- hepatitis B,chronic,
- liver cirrhosis,
- angiotensins

FullText(HTML)

References(22)

References

[1] LOZANO R,NAGHAVI M,FOREMAN K,et al. Global and regional mortality from 235 causes of death for 20 age groups in1990 and 2010:A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.

[2] ZHAO YN,LI H. Advances in anti-hepatitis B virus targets[J]. Int J Virol,2017,24(3):197-200.(in Chinese)赵亚楠，李红．抗乙型肝炎病毒靶点研究进展[J]．国际病毒学杂志，2017,24(3):197-200.

[3] KIM G,BAIK SK. Overview and recent trends of systematic reviews and Meta-analyses in hepatology[J]. Clin Mol Hepatol,2014,20(2):137-150.

[4] YANG Y,ZHANG X. Analysis of reversal factors associated with liver fibrosis/cirrhosis in patients with chronic HBV infection after achieving virologic response[J]. J Clin Hepatol,2018,34(7):1543-1546.(in Chinese)杨艳，张新．慢性HBV感染者获得病毒学应答后肝纤维化/肝硬化逆转因素的分析[J]．临床肝胆病杂志，2018,34(7):1543-1546.

[5] GRANZOW M,SCHIERWAGEN R,KLEIN S,et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis[J]. Hepatology,2014,60(1):334-348.

[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. Guideline of prevention and treatment for chronic hepatitis B(2015 Update)[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[7] HUANG Y,DENG X,LIANG J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis[J]. Exp Cell Res,2017,352(2):420-426.

[8] SIMOES-E-SILVA AC,MIRANDA AS,ROCHA NP,et al.Renin angiotensin system in liver diseases:Friend or foe?[J]. World J Gastroenterol,2017,23(19):3396-3406.

[9] ENGELI S,NEGREL R,SHARMA AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system[J]. Hypertension,2000,35(6):1270-1277.

[10] RODRIGUES PRESTES TR,ROCHA NP,MIRANDA AS. et al.The anti-inflammatory potential of ACE2/angiotensin-(1-7)/mas receptor axis:Evidence frombasic and clinical research[J]. Curr Drug Targets,2017,18(11):1301-1313.

[11] de OLIVEIRA da SILVA B,ALBERICI LC,RAMOS LF,et al.Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7)and mi RNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism[J]. Int J Biochem Cell Biol,2018,98:137-155.

[12] LI YF,HUO LJ,ZHANG J,et al. Effects of Ang(1-7)on Mas receptor,TGF-β1/Smad3,CTGF induced by AngⅡin hepatic stellate cell[J/CD]. Chin J Digest Med Imageol(Electronic Edition),2016,6(3):124-129.(in Chinese)李亚芳，霍丽娟，张婕．等．Ang(1-7)对AngⅡ诱导的肝星状细胞Mas受体、TGF-β1/Samd3、CTGF的影响[J/CD]．中华消化病与影像杂志(电子版)，2016,6(3):124-129.

[13] HU QD,HU ZZ,CHEN QF,et al. BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats[J]. Prostaglandins Other Lipid Mediat,2017,131:75-82.

[14] MENG F,ZHENG Y,ZHANG Q,et al. Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography(FibroScan)[J]. J Ultrasound Med,2015,34(3):403-410.

[15] HASHEMI SA,ALAVIAN SM,GHOLAMI-FESHARAKI M,et al. Assessment of transient elastography(FibroScan)for diagnosis of fibrosis in non-alcoholic fatty liver disease:A systematic review and Meta-analysis[J]. Caspian J Intern Med,2016,7(4):242-252.

[16] LEI JW,TAN BB,LI WB,et al. Value of transient elastography measured with Fibro Touch in the diagnosis of liver fibrosis in chronic hepatitis patients with hepatocellular carcinoma[J].Chin J Med Offic,2017,45(9):930-933.(in Chinese)雷洁雯，谭碧波，李万斌，等．Fibro Touch瞬时弹性成像诊断慢性乙型肝炎合并肝癌患者肝纤维化程度应用研究[J]．临床军医杂志，2017,45(9):930-933.

[17] WU N,ZHANG MY,WU RH. et al. Diagnostic values of FibroScan and FibroTouch for liver fibrosis:A comparative analysis[J]. J Clin Hepatol,2014,30(7):624-627.(in Chinese)吴娜，张明媛，吴瑞红，等．FibroTouch与FibroScan对肝纤维化程度诊断价值的比较分析[J]．临床肝胆病杂志，2014,30(7):624-627.

[18] QI M. Study and analysis of correlation of liver hardness tester FibroTouch and FibroScan with pathological stage of liver[J].China Med Pharm,2016,6(21):218-220.(in Chinese)亓民．研究分析肝脏硬度测定仪FibroTouch与FibroScan与肝脏病理分期的相关性[J]．中国医药科学，2016,6(21):218-220.

[19] SHIM KY,EOM YW,KIM MY,et al. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension Korean[J]. J Intern Med,2018,33(3):453-461.

[20] LI XY,PENG Y,BU XW,et al. Balancing effect of biejiajian oral liquid on ACE-Ang II-AT1R axis and ACE2-Ang-(1-7)-Mas axis in rats with CCl4-induced hepatic fibrosis[J].Chin J Integr Med,2018,24(11):853-859.

[21] YUAN Y,ZHU H. Correlation of serum hyaluronidase with AngⅡin hepatitis B patients[J]. Chongqing Med,2013,42(26):3120-3121.(in Chinese)袁勇，朱洪．乙型肝炎患者血清HA与AngⅡ的相关性研究[J]．重庆医学，2013,42(26):3120-3121.

[22] YANG ZH,SHEN FJ,HUANG HF. Change of AngⅡ，Ang(1-7)and AngⅡ/Ang(1-7)ratio in patients with hepatitis B and HBV-related cirrhosis[J/CD]. Chin J Clinicians(Electronic Edition),2016,10(8):1062-1065.(in Chinese)杨志花，申凤俊，黄会芳．慢性乙型肝炎和肝硬化患者AngⅡ、Ang(1-7)及AngⅡ/Ang(1-7)比值的变化[J/CD]．中华临床医师杂志(电子版)，2016,10(8):1062-1065.

Relative Articles

[1]	Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
[2]	Haimei GUAN, Kan ZHANG, Weiyu CHEN, Guobao LI, Yangling ZENG, Riyun ZHANG, Tianwen WANG, Baohua XIE, Dewen MAO. Mechanism of action and potential value of the IRE1α/TRAF2/JNK pathway in the progression of acute liver failure[J]. Journal of Clinical Hepatology, 2024, 40(6): 1281-1288. doi: 10.12449/JCH240633
[3]	Hepatology｜Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α[J]. Journal of Clinical Hepatology, 2024, 40(9): 1766-1766. doi: 10.12449/JCH2409.gwqkjpwzjj1
[4]	Xing YANG, Shudi LI, Jiangkai LIU, Zhen WANG, Suling LI. Current research status of traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma by regulating the JAK/STAT signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(11): 2718-2729. doi: 10.3969/j.issn.1001-5256.2023.11.030
[5]	Cheng MA, Hui YANG. Role of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway in alcoholic liver disease[J]. Journal of Clinical Hepatology, 2023, 39(7): 1708-1713. doi: 10.3969/j.issn.1001-5256.2023.07.028
[6]	Hua ZHANG, Xuanxuan KOU, Jingxin DENG, Jiangang ZHANG. Regulatory role of hypoxia－inducible factor－1α/Yes－associated protein in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2191-2197. doi: 10.3969/j.issn.1001-5256.2023.09.024
[7]	Rui SONG, Jing LI, Hongju YANG, Minyue LI, Jing YOU. Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2627-2631. doi: 10.3969/j.issn.1001-5256.2022.11.038
[8]	Jinjin ZHAO, Haiguang ZHANG, Feifei CUI, Lei WANG, Qingjiang MO, Luyang JIAO. Effect of hypoxia-inducible factor-1α on stemness and epirubicin sensitivity of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2021, 37(2): 354-357. doi: 10.3969/j.issn.1001-5256.2021.02.021
[9]	Zheng Yang, Wang JiaRu, Liu LuLu, Wang JiaHui, Zhao TieJian. Molecular mechanism of the anti-liver fibrosis effect of curcumol: An analysis based on the TLR4/NF-κB signaling pathway[J]. Journal of Clinical Hepatology, 2020, 36(7): 1508-1513. doi: 10.3969/j.issn.1001-5256.2020.07.013
[10]	Zhao DongKang, Luo WeiWei, Yu ShuiPing. Role of the Wnt signaling pathway in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(11): 2415-2419. doi: 10.3969/j.issn.1001-5256.2018.11.033
[11]	Zhang Xu, Liu Ping, Mu YongPing. Relationship between the Notch signaling pathway and the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 181-183. doi: 10.3969/j.issn.1001-5256.2018.01.039
[12]	Ju Di, Li JingTao, Han Man, Wei HaiLiang, Yan ShuGuang, Li Mi, Shi XiaoYan, Chang ZhanJie. Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway[J]. Journal of Clinical Hepatology, 2018, 34(1): 192-194. doi: 10.3969/j.issn.1001-5256.2018.01.042
[13]	Peng Qin, Zhao ShenJun, Li Wu. Research advances in signaling pathways involved in the development of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(5): 954-958. doi: 10.3969/j.issn.1001-5256.2017.05.035
[14]	Wang Li, Shi Wei, Xue Jun, Pan CuiRan, Yao Min, Yao DengFu. Regulatory effect of abnormal expression of hypoxia- inducible factor- 1α on angiogenesis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(2): 369-374. doi: 10.3969/j.issn.1001-5256.2017.02.037
[15]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[16]	Zhou XueLing, Yu ShuiPing. Role of Wnt signaling pathway in progression of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1540-1542. doi: 10.3969/j.issn.1001-5256.2015.09.045
[17]	Pan Jin, Ju Jian. Current perspectives on the JAK/STAT signaling pathway and its activating factors in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 393-396.
[18]	Zheng Yan, Zhang ChunQing, Wang QiZhi, Huang HaiYan, Wang ZhiNa, Wei Yuan, Xu AnTao. Differential expression of OPN, VEGF-A, and HIF-1α and its clinical significance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(1): 58-61.
[19]	Gou ZePeng, Wang DeSheng, Zhou Liang, Zhu PuLi, Zhang Yong, Sun Wei. The research progress of STAT3 on the regulation of hepatocellular carcinoma invasion and metastasis[J]. Journal of Clinical Hepatology, 2012, 28(4): 308-311.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	马玉洁，姬群英. 原发性胆汁性肝硬化诊治进展. 大医生. 2022(22): 98-101 .
2.	党富涛，唐映梅. 自身抗体在原发性胆汁性胆管炎中的诊断及预后价值. 临床肝胆病杂志. 2020(05): 1164-1166 . 本站查看
3.	吴蓉，冷爱民. 原发性胆汁性胆管炎合并自身免疫性溶血性贫血1例报告. 临床肝胆病杂志. 2020(12): 2795-2797 . 本站查看
4.	杨剑. 胆管阻塞患者PTCD治疗后肝损伤、炎症和胆汁淤积的预后影响因素及护理策略. 国际护理学杂志. 2020(20): 3696-3700 .
5.	赵敏，李勤光，卓传尚. 乙型病毒性肝炎与原发性胆汁性胆管炎患者血清抗线粒体抗体M2亚型表达的特征分析. 现代检验医学杂志. 2020(06): 16-20 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1445) PDF downloads(252)

Correlation of the levels of angiotensin Ⅱ and angiotensin (1-7) with the degree of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.11.015